Evidence map›Paper›PMID 35268783›Full record

ArticleMolecules (Basel, Switzerland)2022

New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4.

Dario P Anobile, Mauro Niso, Adrian Puerta, Stephanie M Fraga Rodrigues, Francesca S Abatematteo, Amir Avan, Carmen Abate, Chiara Riganti, Elisa Giovannetti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Development of Fluorescent 4-[4-(3Journal of medicinal chemistry · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Dario P AnobileDepartment of Oncology, University of Torino, Via Santena 5/bis, 10026 Torino, Italy.
Mauro NisoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy.
Adrian PuertaDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.ORCID 0000-0002-7975-1960
Stephanie M Fraga RodriguesDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.
Francesca S AbatematteoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-6297-6234
Amir AvanBasic Medical Sciences Institute, Mashhad University of Medical Science, Mashhad 91886-17871, Iran.ORCID 0000-0002-4968-0962
Carmen AbateDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-9292-884X
Chiara RigantiDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.ORCID 0000-0001-9787-4836
Elisa GiovannettiDepartment of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.ORCID 0000-0002-7565-7504
Cancer Center Amsterdam · NLUniversity of Bari Aldo Moro · ITFondazione Pisa · ITMashhad University of Medical Sciences · IRUniversidad de La Laguna · ES

Funding

CCA Foundation 2018CRT Foundation 2021-0556European Cooperation in Science and Technology CA17104Italian Association for Cancer Research 24444, 21408KWF Dutch Cancer Society 19571, 13598
6 · The paper itself

Abstract

A new sigma-2 (σ2) receptor ligand (

Indexed as

Antineoplastic AgentsApoptosisCell MovementCell ProliferationPancreatic NeoplasmsThiosemicarbazonesAdenocarcinomaCarcinoma, Pancreatic DuctalCell Line, TumorDeoxycytidineGemcitabineHumansReceptors, sigmaAntineoplastic AgentsDeoxycytidineGemcitabineReceptors, sigmasigma-2 receptorThiosemicarbazoneschemoresistancemigrationmultifunctional thiosemicarbazonepancreatic cancer primary culturesσ-2 receptor ligands

Identifiers

PMID35268783
PMCPMC8911630
OpenAlexW4220794634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.